Announcements Trials
Browse Landscape

Status

Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 77Observational 4Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1

Conditions

Gastrointestinal Neoplasms 2Gastrointestinal Stromal Tumors 1

Interventions

regorafenib 3Sunitinib 2Ramucirumab 2Oxaliplatin 2Fluorouracil 2zenocutuzumab 1zanidatamab 1ulixertinib 1trifluridine tipiracil drug combination 1sodium thiosulfate 1selpercatinib 1ripretinib 1peginterferon alfa-2a 1pegilodecakin 1onvansertib 1omburtamab I-131 1guselkumab 1futibatinib 1derazantinib 1balstilimab 1avapritinib 1Tenofovir 1Taxes 1Proton Pump Inhibitors 1Paclitaxel 1Melphalan 1Leucovorin 1Laparoscopy 1Imatinib Mesylate 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Sunitinib × Gastrointestinal × Clear all
NCT06948955 2026-05-08

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Available
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT00094029 2012-03-09

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Pfizer

Approved for marketing
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡